We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

60 hedge funds and large institutions have $311M invested in Karyopharm Therapeutics in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

53% more capital invested

Capital invested by funds: $204M → $311M (+$107M)

11% more funds holding

Funds holding: 54 → 60 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

25% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 24

Holders
60
Holders Change
+6
Holders Change %
+11.11%
% of All Funds
1.73%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
18
Reduced
24
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$41.3M
2
BA
BlackRock Advisors
Delaware
+$10.5M
3
CAM
Cormorant Asset Management
Massachusetts
+$6.08M
4
BlackRock
BlackRock
New York
+$2.59M
5
GC
Guggenheim Capital
Illinois
+$2.48M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$19.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$4.14M
3
TG
TCW Group
California
-$3.91M
4
Morgan Stanley
Morgan Stanley
New York
-$3.52M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS AM
26
UBS AM
Illinois
$1.44M -$6.59K -13 -0.4%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$1.38M +$310K +611 +26%
MOACM
28
Mutual of America Capital Management
New York
$1.31M +$1.43M +2,827 New
ARC
29
Absolute Return Capital
Massachusetts
$1.15M +$1.26M +2,480 New
RFC
30
Russell Frank Company
Washington
$1.05M +$1.39M +2,746 New
TCIM
31
TIAA CREF Investment Management
New York
$919K +$312K +615 +45%
Ameriprise
32
Ameriprise
Minnesota
$845K +$925K +1,825 New
Bank of America
33
Bank of America
North Carolina
$739K +$770K +1,519 +1,973%
BIM
34
BlackRock Investment Management
Delaware
$695K +$89.7K +177 +13%
Goldman Sachs
35
Goldman Sachs
New York
$663K +$725K +1,430 New
Charles Schwab
36
Charles Schwab
California
$531K +$14.2K +28 +3%
SIM
37
Spark Investment Management
New York
$524K -$243K -480 -30%
ARTA
38
A.R.T. Advisors
New York
$471K +$516K +1,018 New
Morgan Stanley
39
Morgan Stanley
New York
$469K -$3.52M -6,953 -87%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$439K – – –
FM
41
Forward Management
California
$396K -$1.01M -1,983 -58%
CS
42
Credit Suisse
Switzerland
$380K +$415K +819 New
PIM
43
Partner Investment Management
California
$375K -$608K -1,199 -60%
TA
44
Teachers Advisors
New York
$346K +$6.08K +12 +2%
N
45
Nuveen
North Carolina
$322K -$275K -542 -44%
NFA
46
Nationwide Fund Advisors
Ohio
$312K -$89.2K -176 -21%
AI
47
Analytic Investors
California
$273K +$299K +589 New
ProShare Advisors
48
ProShare Advisors
Maryland
$244K +$268K +528 New
MLICM
49
Metropolitan Life Insurance Company (MetLife)
New York
$196K -$131K -258 -38%
AIG
50
American International Group
New York
$164K +$4.56K +9 +3%
1
2
3

KPTI Hedge Fund Activity: Q1 2014 in Review

60 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2014, worth a combined $311M — up 53% from $204M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KPTI positions and 9 closed out — a net gain of 6 holders — while 18 added to existing stakes and 24 trimmed.

The largest buyer was Franklin Resources, adding an estimated $41.3M. The largest seller was PFM Health Sciences, cutting an estimated $19.6M.

  • 60 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2014, up from 54 in Q4 2013.
  • Funds reported $311M of Karyopharm Therapeutics stock for Q1 2014, up 53% quarter-over-quarter.
  • 15 funds opened new Karyopharm Therapeutics positions in Q1 2014 and 9 closed out, a net change of +6 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2014 was Franklin Resources, an estimated $41.3M added.
  • The largest Karyopharm Therapeutics seller in Q1 2014 was PFM Health Sciences, an estimated $19.6M sold.

Based on aggregated 13F filings for Q1 2014.